Psyon s.r.o.

The medical center is at the forefront of research into treatment-resistant depression, focusing on innovative therapeutic approaches. The center is exploring the efficacy of novel compounds like COMP360, administered with psychological support, to improve depressive symptoms.

• Innovative therapeutic compounds
• Psychological support integration
• Symptom improvement strategies

By investigating these advanced treatments, the center aims to provide new hope for patients who have not responded to traditional therapies.

Specializing in major depressive disorder, the center conducts extensive research on the long-term safety and effectiveness of treatments like NMRA-335140. This includes evaluating its impact on depressive symptoms and overall patient well-being.

• Long-term treatment safety
• Effectiveness of kappa opioid receptor antagonists
• Patient well-being enhancement

The center's work in this area is crucial for developing sustainable treatment options that improve quality of life for individuals with MDD.

In the field of ischemic heart disease, the center is pioneering research into the regression of atherosclerosis through innovative therapies. This includes the use of psilocybin-assisted psychotherapy to potentially reduce plaque volume in coronary arteries.

• Atherosclerosis regression techniques
• Psilocybin-assisted psychotherapy
• Coronary artery health improvement

Through these studies, the center aims to revolutionize the treatment of coronary artery disease, offering new pathways to cardiovascular health.